WO2005116212A3 - Treatment of neurodegenerative disease through intracranial delivery of sirna - Google Patents
Treatment of neurodegenerative disease through intracranial delivery of sirna Download PDFInfo
- Publication number
- WO2005116212A3 WO2005116212A3 PCT/US2005/018144 US2005018144W WO2005116212A3 WO 2005116212 A3 WO2005116212 A3 WO 2005116212A3 US 2005018144 W US2005018144 W US 2005018144W WO 2005116212 A3 WO2005116212 A3 WO 2005116212A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- catheter
- type
- sirna
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002565098A CA2565098A1 (en) | 2004-05-25 | 2005-05-24 | Treatment of neurodegenerative disease through intracranial delivery of sirna |
EP05752920A EP1766009A2 (en) | 2004-05-25 | 2005-05-24 | Treatment of neurodegenerative disease through intracranial delivery of sirna |
AU2005248389A AU2005248389A1 (en) | 2004-05-25 | 2005-05-24 | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
JP2007515250A JP2008500049A (en) | 2004-05-25 | 2005-05-24 | Treatment of neurodegenerative diseases by intracranial delivery of siRNA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/852,997 | 2004-05-25 | ||
US10/852,997 US7829694B2 (en) | 2002-11-26 | 2004-05-25 | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005116212A2 WO2005116212A2 (en) | 2005-12-08 |
WO2005116212A3 true WO2005116212A3 (en) | 2006-05-11 |
Family
ID=35207382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/018144 WO2005116212A2 (en) | 2004-05-25 | 2005-05-24 | Treatment of neurodegenerative disease through intracranial delivery of sirna |
Country Status (6)
Country | Link |
---|---|
US (1) | US7829694B2 (en) |
EP (2) | EP2371959A3 (en) |
JP (1) | JP2008500049A (en) |
AU (1) | AU2005248389A1 (en) |
CA (1) | CA2565098A1 (en) |
WO (1) | WO2005116212A2 (en) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
US7618948B2 (en) * | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
WO2006002283A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
CN102775472A (en) | 2003-01-06 | 2012-11-14 | 安吉奥开米公司 | Aprotinin and analogue as carriers across the blood-brain barrier |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
ES2485848T3 (en) * | 2003-09-12 | 2014-08-14 | University Of Massachusetts | RNA interference for the treatment of disorders related to function gain |
US8680063B2 (en) * | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
ES2383901T5 (en) * | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Aprotinin polypeptides to transport a compound through the blood-brain barrier |
WO2006121960A2 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
EP1896586A2 (en) | 2005-06-28 | 2008-03-12 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
PL2233156T3 (en) | 2005-07-15 | 2013-09-30 | Angiochem Inc | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
WO2007022506A2 (en) * | 2005-08-18 | 2007-02-22 | University Of Massachusetts | Methods and compositions for treating neurological disease |
GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CA2954376C (en) | 2006-10-16 | 2019-06-11 | Bionomics Limited | Novel anxiolytic compounds |
US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US7988668B2 (en) | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US7819842B2 (en) | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US8173614B2 (en) * | 2007-01-03 | 2012-05-08 | Medtronic, Inc. | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof |
US8183219B2 (en) * | 2007-01-03 | 2012-05-22 | Medtronic, Inc. | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof |
US20080171906A1 (en) * | 2007-01-16 | 2008-07-17 | Everaerts Frank J L | Tissue performance via hydrolysis and cross-linking |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
JP2010527375A (en) * | 2007-05-15 | 2010-08-12 | ヘリコン セラピューティクス,インコーポレイテッド | Method for treating cognitive impairment by inhibition of GPR12 |
MX2009012315A (en) * | 2007-05-15 | 2009-12-03 | Helicon Therapeutics Inc | Methods of identifying genes involved in memory formation using small interfering rna(sirna). |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
JP5049713B2 (en) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | GAME SYSTEM, GAME DEVICE COMPRISING THE SAME, AND PROBLEM NOTIFICATION DEVICE |
ES2721148T3 (en) * | 2008-04-18 | 2019-07-29 | Angiochem Inc | Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use |
EP2346896A4 (en) | 2008-10-15 | 2014-06-25 | Angiochem Inc | Etoposide and doxorubicin conjugates for drug delivery |
EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | Conjugates of glp-1 agonists and uses thereof |
BRPI0922689A2 (en) * | 2008-12-05 | 2018-11-06 | Angiochem Inc. | neurotensin conjugates or neurotensin analogs and uses thereof |
JP2012512185A (en) | 2008-12-17 | 2012-05-31 | アンジオケム インコーポレーテッド | Membrane type 1 matrix metalloprotein inhibitor and use thereof |
JP2012524030A (en) | 2009-04-20 | 2012-10-11 | アンジオケム インコーポレーテッド | Treatment of ovarian cancer with an anticancer agent conjugated to an angiopep-2 analog |
BRPI1015918A2 (en) | 2009-07-02 | 2019-09-24 | Angiochem Inc | multimeric peptide conjugates and uses thereof |
WO2011087804A2 (en) | 2009-12-21 | 2011-07-21 | Medtronic, Inc. | Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
WO2011130347A2 (en) * | 2010-04-13 | 2011-10-20 | The Johns Hopkins University | Methods for enhancing axonal regeneration |
US8805519B2 (en) | 2010-09-30 | 2014-08-12 | Nevro Corporation | Systems and methods for detecting intrathecal penetration |
TWI417109B (en) | 2010-12-30 | 2013-12-01 | Univ Ishou | A short hairpin rna for gene knockdown of the n-methyl-d-aspartate receptor nr1 subunit, an use of a short hairpin rna in manufacturing a reagent foe gene knockdown of the n-methyl-d-aspartate receptor nr1 subunit and a medication to release skin inflamm |
AU2012222869B2 (en) * | 2011-03-02 | 2015-08-13 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
NZ615466A (en) | 2011-05-12 | 2016-02-26 | Bionomics Ltd | Methods for preparing naphthyridines |
AU2013211937B2 (en) | 2012-01-25 | 2016-07-28 | Nevro Corporation | Lead anchors and associated systems and methods |
US20150147812A1 (en) | 2012-05-30 | 2015-05-28 | Lsip, Llc | Carrier for gene introduction use, gene introduction agent, methods for producing said carrier and said gene introduction agent, and method for introducing gene into cell |
US9265935B2 (en) | 2013-06-28 | 2016-02-23 | Nevro Corporation | Neurological stimulation lead anchors and associated systems and methods |
WO2015143245A1 (en) * | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
CN116970607A (en) | 2014-03-19 | 2023-10-31 | Ionis制药公司 | Compositions for modulating ataxin 2 expression |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
CN108603174A (en) * | 2015-12-01 | 2018-09-28 | 星火治疗有限公司 | The expandable method of recombinant adeno-associated virus (AAV) carrier is generated the serum free suspension cell culture system suitable for clinical application |
US10980999B2 (en) | 2017-03-09 | 2021-04-20 | Nevro Corp. | Paddle leads and delivery tools, and associated systems and methods |
EP3758793A4 (en) | 2018-03-29 | 2021-12-08 | Nevro Corp. | Leads having sidewall openings, and associated systems and methods |
JP7379387B2 (en) | 2018-06-05 | 2023-11-14 | エフ. ホフマン-ラ ロシュ アーゲー | Oligonucleotides for controlling ATXN2 expression |
SG11202100077PA (en) | 2018-07-25 | 2021-02-25 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn2 expression |
US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
CN111214461B (en) * | 2020-03-24 | 2021-04-16 | 河南大学 | Preparation and application of sugar-targeted modified siRNA (small interfering ribonucleic acid) nanoparticles |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040874A1 (en) * | 1996-04-30 | 1997-11-06 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
WO2001049844A1 (en) * | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
WO2003047676A1 (en) * | 2001-11-30 | 2003-06-12 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors |
WO2003070895A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
WO2004013280A2 (en) * | 2002-08-05 | 2004-02-12 | University Of Iowa Research Foundation | ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING |
WO2004047872A2 (en) * | 2002-11-26 | 2004-06-10 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
WO2004101787A1 (en) * | 2003-05-14 | 2004-11-25 | Japan Science And Technology Agency | Inhibition of the expression of huntington gene |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
WO2005045034A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US634233A (en) * | 1898-12-20 | 1899-10-03 | Harold P Dyer | Apparatus for treating saccharine solutions. |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB2181691B (en) | 1985-10-21 | 1990-05-23 | Porvair Ltd | Gloves |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5800390A (en) | 1991-05-24 | 1998-09-01 | Sumitomo Pharmaceuticals Company, Limited | Equipment for intracerebral administration of preparations |
US5236908A (en) | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
FR2685346B1 (en) * | 1991-12-18 | 1994-02-11 | Cis Bio International | PROCESS FOR THE PREPARATION OF DOUBLE-STRANDED RNA, AND ITS APPLICATIONS. |
CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
US5354326A (en) | 1993-01-27 | 1994-10-11 | Medtronic, Inc. | Screening cable connector for interface to implanted lead |
AU7568094A (en) | 1993-08-12 | 1995-03-14 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
AU7676894A (en) | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
AU1552995A (en) | 1993-12-17 | 1995-07-03 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
ATE386131T1 (en) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | AAV-MEDIATED DELIVERY OF DNA INTO CELLS OF THE NERVOUS SYSTEM |
US6294202B1 (en) | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
WO1996018736A2 (en) | 1994-12-13 | 1996-06-20 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
US5534350A (en) | 1994-12-28 | 1996-07-09 | Liou; Derlin | Powerfree glove and its making method |
US7069634B1 (en) | 1995-04-28 | 2006-07-04 | Medtronic, Inc. | Method for manufacturing a catheter |
WO1996033761A1 (en) | 1995-04-28 | 1996-10-31 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
US5840059A (en) | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5942455A (en) | 1995-11-14 | 1999-08-24 | Drexel University | Synthesis of 312 phases and composites thereof |
JPH09268067A (en) | 1996-03-29 | 1997-10-14 | Asahi Glass Co Ltd | Production of silicon carbide member |
WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US7189222B2 (en) | 1996-04-30 | 2007-03-13 | Medtronic, Inc. | Therapeutic method of treatment of alzheimer's disease |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
WO1998012311A2 (en) | 1996-09-11 | 1998-03-26 | The General Hospital Corporation | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
US5882561A (en) | 1996-11-22 | 1999-03-16 | Drexel University | Process for making a dense ceramic workpiece |
GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
US5968059A (en) | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
GB9706463D0 (en) | 1997-03-27 | 1997-05-14 | Medical Res Council | A model of inflamation in the central nervous system for use in the study of disease |
US6436708B1 (en) | 1997-04-17 | 2002-08-20 | Paola Leone | Delivery system for gene therapy to the brain |
US5782892A (en) | 1997-04-25 | 1998-07-21 | Medtronic, Inc. | Medical lead adaptor for external medical device |
US5931861A (en) | 1997-04-25 | 1999-08-03 | Medtronic, Inc. | Medical lead adaptor having rotatable locking clip mechanism |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6110459A (en) | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
US20050282198A1 (en) | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
US6187906B1 (en) | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
US6231969B1 (en) | 1997-08-11 | 2001-05-15 | Drexel University | Corrosion, oxidation and/or wear-resistant coatings |
WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
US6151525A (en) | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
AU3117799A (en) | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
ES2326893T3 (en) | 1998-05-27 | 2009-10-21 | Genzyme Corporation | AAV VECTORS FOR THE MANUFACTURE OF MEDICINES FOR ADMINISTRATION POTENTIATED BY CONVECTION. |
US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US6313268B1 (en) | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
US6319905B1 (en) | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
US6835194B2 (en) * | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6331427B1 (en) * | 1999-03-26 | 2001-12-18 | Millennium Pharmaceuticals, Inc. | Protease homologs |
AU4806100A (en) | 1999-04-28 | 2000-11-10 | Board Of Trustees Of The Leland Stanford Junior University | P element derived vector and methods for its use |
CA2403243A1 (en) | 1999-08-31 | 2001-03-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based modulators of gene expression |
GB9928248D0 (en) | 1999-12-01 | 2000-01-26 | Gill Steven S | An implantable guide tube for neurosurgery |
US6310048B1 (en) | 1999-12-09 | 2001-10-30 | St. Louis University | Antisense modulation of amyloid beta protein expression |
US6461989B1 (en) | 1999-12-22 | 2002-10-08 | Drexel University | Process for forming 312 phase materials and process for sintering the same |
US20030092003A1 (en) | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
AU2001238612A1 (en) | 2000-02-18 | 2001-08-27 | The Regents Of The University Of California | Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
AU2001247244B2 (en) | 2000-02-28 | 2005-06-02 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
US6945969B1 (en) | 2000-03-31 | 2005-09-20 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6551290B1 (en) | 2000-03-31 | 2003-04-22 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
WO2001091801A2 (en) | 2000-05-26 | 2001-12-06 | Chiron Corporation | Methods of transducing neural cells using lentivirus vectors |
US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
AU2001288317A1 (en) | 2000-08-30 | 2002-03-13 | Agion Technologies, Llc | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties |
US20050209179A1 (en) | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US6659995B1 (en) | 2000-11-17 | 2003-12-09 | Syde A. Taheri | Autologous myocyte micro granual retrieval and implantation (AMMGRI) |
CA2327208A1 (en) | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
DK2813582T3 (en) | 2000-12-01 | 2017-07-31 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | Small RNA molecules that mediate RNA interference |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
AU2002256418A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
EP1409737A4 (en) | 2001-06-15 | 2005-10-12 | Interleukin Genetics Inc | Methods for detecting and treating the early onset of aging-related conditions |
AU2002326589B2 (en) | 2001-08-07 | 2008-06-05 | University Of Delaware | Compositions and methods for the prevention and treatment of Huntington's disease |
US6944497B2 (en) | 2001-10-31 | 2005-09-13 | Medtronic, Inc. | System and method of treating stuttering by neuromodulation |
US20030120327A1 (en) | 2001-12-20 | 2003-06-26 | Mark Tobritzhofer | Medical lead adaptor assembly with retainer |
US20030120282A1 (en) | 2001-12-24 | 2003-06-26 | Scouten Charles W. | Stereotaxic manipulator with retrofitted linear scales and digital display device |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US7270653B2 (en) | 2002-02-20 | 2007-09-18 | Abbott Research Group | Methods of treating abnormal biological conditions using metal oxides |
US20030224512A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
US20040023855A1 (en) | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
US20040018520A1 (en) | 2002-04-22 | 2004-01-29 | James Thompson | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
US7008403B1 (en) | 2002-07-19 | 2006-03-07 | Cognitive Ventures Corporation | Infusion pump and method for use |
AU2002368132A1 (en) | 2002-07-25 | 2004-02-16 | Nissei Kabushiki Kaisha | Roll cone manufacturing device |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
WO2006002283A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20050048641A1 (en) * | 2002-11-26 | 2005-03-03 | Medtronic, Inc. | System and method for delivering polynucleotides to the central nervous system |
US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US20040186528A1 (en) | 2003-03-20 | 2004-09-23 | Medtronic, Inc. | Subcutaneous implantable medical devices with anti-microbial agents for chronic release |
US8512290B2 (en) | 2003-03-20 | 2013-08-20 | Boston Scientific Scimed, Inc. | Devices and methods for delivering therapeutic or diagnostic agents |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
HUE026861T2 (en) | 2003-05-01 | 2016-07-28 | Genzyme Corp | Gene therapy for neurometabolic disorders |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
US7917228B2 (en) | 2003-05-13 | 2011-03-29 | Medtronic, Inc. | Medical lead adaptor assembly |
US20060014165A1 (en) | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
ES2485848T3 (en) | 2003-09-12 | 2014-08-14 | University Of Massachusetts | RNA interference for the treatment of disorders related to function gain |
WO2005065242A2 (en) | 2003-12-29 | 2005-07-21 | Am Biosolutions | Method of treating cancer using platelet releasate |
WO2005070104A2 (en) | 2004-01-09 | 2005-08-04 | The University Of Tennessee Research Foundation | REAL-TIME POLYMERASE CHAIN REACTION-BASED GENOTYPING ASSAY FOR β2-ADRENERGIC RECEPTOR SINGLE NUCLEODITE POLYMORPHISM |
US20050202075A1 (en) | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
EP1735443A2 (en) * | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
WO2006022639A1 (en) | 2004-07-21 | 2006-03-02 | Applera Corporation | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
EP1807157A2 (en) | 2004-10-22 | 2007-07-18 | Neurologix, Inc. | Use of apoptosis inhibiting compounds in degenerative neurological disorders |
NL1028134C2 (en) | 2005-01-27 | 2006-07-31 | Sara Lee De Nv | Method for preparing a drink suitable for consumption from at least two ingredients to be dissolved and / or extracted and an amount of liquid. |
TW200635542A (en) | 2005-04-01 | 2006-10-16 | Dharma Drum Mountain | Method of establishing and using commemorative material |
WO2006121960A2 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US20080280843A1 (en) | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
GB0520235D0 (en) | 2005-10-05 | 2005-11-16 | Astrazeneca Ab | Method |
AU2006305886C1 (en) | 2005-10-28 | 2011-03-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CN200970210Y (en) | 2006-10-12 | 2007-11-07 | 王会才 | Cleaning and dewatering machine for mop |
-
2004
- 2004-05-25 US US10/852,997 patent/US7829694B2/en not_active Expired - Fee Related
-
2005
- 2005-05-24 CA CA002565098A patent/CA2565098A1/en not_active Abandoned
- 2005-05-24 JP JP2007515250A patent/JP2008500049A/en active Pending
- 2005-05-24 AU AU2005248389A patent/AU2005248389A1/en not_active Abandoned
- 2005-05-24 WO PCT/US2005/018144 patent/WO2005116212A2/en active Application Filing
- 2005-05-24 EP EP11171337.6A patent/EP2371959A3/en not_active Withdrawn
- 2005-05-24 EP EP05752920A patent/EP1766009A2/en not_active Withdrawn
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040874A1 (en) * | 1996-04-30 | 1997-11-06 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
WO2001049844A1 (en) * | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
WO2003047676A1 (en) * | 2001-11-30 | 2003-06-12 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors |
WO2003070895A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
WO2004013280A2 (en) * | 2002-08-05 | 2004-02-12 | University Of Iowa Research Foundation | ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING |
WO2004058940A2 (en) * | 2002-08-05 | 2004-07-15 | University Of Iowa Research Foundation | Sirna-mediated gene silencing |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
WO2004047872A2 (en) * | 2002-11-26 | 2004-06-10 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
WO2004101787A1 (en) * | 2003-05-14 | 2004-11-25 | Japan Science And Technology Agency | Inhibition of the expression of huntington gene |
WO2005045034A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
Non-Patent Citations (5)
Title |
---|
GOTO J ET AL: "SUPPRESSION OF HUNTINGTIN GENE EXPRESSION BY SIRNA: A POSSIBLE THERAPEUTIC TOOL FOR HUNTINGTON'S DISEASE", NEUROLOGY, vol. 60, no. 5, SUPPL 1, 11 March 2003 (2003-03-11), pages A286, XP009029181, ISSN: 0028-3878 * |
LIU, W. ET AL.: "Specific inhibition of Huntington's disease gene expression by siRNAs in cultures cells.", PROCEEDINGS OF THE JAPAN ACADEMY. SERIES B, PHYSICAL AND BIOLOGICAL SCIENCES, vol. 79B, no. 10, December 2003 (2003-12-01), pages 293 - 298, XP002983007, ISSN: 0386-2208 * |
MILLER V M ET AL: "Allele-specific silencing of dominant disease genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 100, no. 12, 10 June 2003 (2003-06-10), pages 7195 - 7200, XP002278730, ISSN: 0027-8424 * |
SAPRU M K ET AL: "SMALL INTERFERING RNA ( SIRNA )-MEDIATED SILENCING OF ALPHA -SYNUCLEIN GENE EXPRESSION", ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE, 2003, XP001204566 * |
XIA H ET AL: "RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia", NATURE MEDICINE, vol. 10, no. 8, August 2004 (2004-08-01), pages 816 - 820, XP002311180, ISSN: 1078-8956 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005116212A2 (en) | 2005-12-08 |
EP2371959A3 (en) | 2014-12-10 |
US7829694B2 (en) | 2010-11-09 |
CA2565098A1 (en) | 2005-12-08 |
EP1766009A2 (en) | 2007-03-28 |
AU2005248389A1 (en) | 2005-12-08 |
EP2371959A2 (en) | 2011-10-05 |
US20040220132A1 (en) | 2004-11-04 |
JP2008500049A (en) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005116212A3 (en) | Treatment of neurodegenerative disease through intracranial delivery of sirna | |
WO2004047872A3 (en) | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) | |
WO2008021149A3 (en) | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna | |
WO2007022506A3 (en) | Methods and compositions for treating neurological disease | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
WO2008074329A3 (en) | Modulation of activity of proneurotrophins | |
WO2007133812A3 (en) | Improved carriers for delivery of nucleic acid agents to cells and tissues | |
WO2007141346A3 (en) | Genes regulating intracellular cholesterol trafficking as targets for treatment of cholesterol-related diseases | |
WO2011090741A3 (en) | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 | |
WO2008104978A3 (en) | Novel sirna structures | |
WO2007141796A3 (en) | Therapeutic uses of inhibitors of rtp801l | |
MX2009007136A (en) | Method of providing disease-specific binding molecules and targets. | |
WO2008021210A3 (en) | Methods and compositions for the treatment of neurodegenerative disorders | |
WO2007084684A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
WO2006023544A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
WO2006083797A3 (en) | Improving and protecting cell therapy for neurological disorders including parkinson's disease | |
TW200510458A (en) | Humanized antibodies that recognize beta amyloid peptide | |
WO2007109097A3 (en) | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF | |
WO2010135695A3 (en) | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 | |
WO2006048450A3 (en) | Peptides for use in the treating obesity | |
TW200628473A (en) | Novel heterocycles | |
WO2011025862A3 (en) | Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1 | |
EP2977452A3 (en) | Methods of treatment and prevention of neurodegenerative diseases and disorders | |
MX2009008413A (en) | Treatment and prevention of neurodegenerative diseases using gene therapy. | |
WO2008020864A3 (en) | Imaging correlates of neurogenesis with mri |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005248389 Country of ref document: AU Ref document number: 2565098 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005248389 Country of ref document: AU Date of ref document: 20050524 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005248389 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007515250 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005752920 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005752920 Country of ref document: EP |